Antibiotic Exposure Does Not Impact Anti-BRAF/Anti-MEK Targeted Therapy Outcome in Patients with Advanced Melanoma
Current Oncology · 2025
DOI: 10.3390/curroncol32110630 ↗Kurz gefasst
Fachartikel in der Zeitschrift Current Oncology, 2025. Verfasst von Yu Shi Wang und 12 weiteren Autor:innen. Beteiligte Einrichtung: Internal Medicine Division, Department of Medicine, Centre Hospitalier de l'Université de Montréal (CHUM), Montreal, QC H2X 1R6, Canada. Hauptthemen laut MEDLINE: Melanoma, Anti-Bacterial Agents, Proto-Oncogene Proteins B-raf, Protein Kinase Inhibitors. Die Arbeit nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Seerave Foundation, Fonds de recherche du Québec—Santé, Weston Family Foundation.
Abstract (Originalsprache)
The gut microbiome is an established predictor of response to immune checkpoint inhibitors (ICI) in melanoma, and antibiotic exposure prior to ICI initiation is a validated negative prognostic factor. About half of melanoma patients harbor BRAF mutations and are treated with BRAF/MEK inhibitors (BRAFi/MEKi). While the detrimental impact of antibiotics is well described in the ICI setting, their effect on BRAFi/MEKi efficacy remains unknown. We retrospectively analyzed 49 advanced BRAF-mutant melanoma patients treated with BRAFi/MEKi. Antibiotic-exposed patients were compared with non-exposed patients across three time windows: within 30, 60, or 90 days before and after therapy initiation. Outcomes included progression-free survival (PFS), overall survival (OS), and overall response rate (ORR). Among the cohort, 41% had antibiotic exposure within ±30 days, 53% within ±60 days, and 57% within ±90 days. Baseline characteristics were comparable between groups, except for worse ECOG scores in antibiotic-exposed patients. Across all windows, ORR, PFS, and OS were comparable between groups. Unlike what was observed in the ICI setting, antibiotic use did not negatively affect outcomes with BRAFi/MEKi. Despite small sample size, these findings suggest that the detrimental prognostic impact of antibiotics is specific to immunotherapy, highlighting the importance of evaluating the microbiome as a predictive biomarker across treatment contexts.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Internal Medicine Division, Department of Medicine, Centre Hospitalier de l'Université de Montréal (CHUM), Montreal, QC H2X 1R6, Canada.
- Axe Cancer, Centre de Recherche du Centre Hospitalier de l'Université de Montréal (CRCHUM), Montreal, QC H2X 0A9, Canada.
- Hematology-Oncology Division, Department of Medicine, Centre Hospitalier de l'Université de Montréal (CHUM), Montreal, QC H2X 1R6, Canada.
ORCID-Profile: Yu Shi Wang, Qing Yin Wang, Julie Malo, Antoine Desilets
Förderung
- Seerave Foundation
- Fonds de recherche du Québec—Santé
- Weston Family Foundation
- Canadian Cancer Society
- Cancer Research Society
- SITC-MRA Women in Melanoma Award
Zitieren
APA
Wang, Y. S., Wang, Q. Y., Moise, A. E., Syed, H. C., Malo, J., Soberano, S., Belkaid, W., Messaoudene, M., Bélanger, K., Desilets, A., Jamal, R., Routy, B., & Elkrief, A. (2025). Antibiotic Exposure Does Not Impact Anti-BRAF/Anti-MEK Targeted Therapy Outcome in Patients with Advanced Melanoma. Current Oncology. https://doi.org/10.3390/curroncol32110630
Vancouver
Wang YS, Wang QY, Moise AE, Syed HC, Malo J, Soberano S, et al. Antibiotic Exposure Does Not Impact Anti-BRAF/Anti-MEK Targeted Therapy Outcome in Patients with Advanced Melanoma. Current Oncology. 2025. doi:10.3390/curroncol32110630
BibTeX
@article{Wang2025,
author = {Wang, Yu Shi and Wang, Qing Yin and Moise, Alexia Erika and Syed, Hamida Claudia and Malo, Julie and Soberano, Spencer and Belkaid, Wiam and Messaoudene, Meriem and Bélanger, Karl and Desilets, Antoine and Jamal, Rahima and Routy, Bertrand and Elkrief, Arielle},
title = {Antibiotic Exposure Does Not Impact Anti-BRAF/Anti-MEK Targeted Therapy Outcome in Patients with Advanced Melanoma},
journal = {Current Oncology},
year = {2025},
doi = {10.3390/curroncol32110630}
}
EUVIMED